In vitro pharmacokinetic/pharmacodynamic activity of NXL103 versus clindamycin and linezolid against clinical Staphylococcus aureus and Streptococcus pyogenes isolates

International Journal of Antimicrobial Agents

Volumn 38, Issue 4, 2011, Pages 301-306

  Vidaillac, Celine ^a,e   Parra Ruiz, Jorge ^a,b   Winterfield, Patricia ^a   Rybak, Michael J ^a,c,d  

^a WAYNE STATE UNIVERSITY   (United States)

^b HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DETROIT RECEIVING HOSPITAL   (United States)

^e CNRS   (France)

Author keywords

In vitro PK PD model; MRSA; NXL103; Oral streptogramin; Streptococcus pyogenes

Indexed keywords

CLINDAMYCIN; FLOPRISTIN; FLOPRISTIN PLUS LINOPRISTIN; LINEZOLID; LINOPRISTIN; NXL 103; STREPTOGRAMIN DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BIOLOGICAL MODEL; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG PROTEIN BINDING; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PHENOTYPE; PRIORITY JOURNAL; STREPTOCOCCUS PYOGENES;

ACETAMIDES; ANTI-BACTERIAL AGENTS; CLINDAMYCIN; DRUG COMBINATIONS; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STEM CELLS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; STREPTOGRAMIN A; STREPTOGRAMIN B;

EID: 80052272224     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2011.04.023     Document Type: Article

References (26)

1. J. Edelsberg, C. Taneja, M. Zervos, N. Haque, C. Moore, and K. Reyes Trends in US hospital admissions for skin and soft tissue infections Emerg Infect Dis 15 2009 1516 1518
2. R.A. Seaton, D. Nathwani, P. Burton, C. McLaughlin, A.R. MacKenzie, and S. Dundas Point prevalence survey of antibiotic use in Scottish hospitals utilising the Glasgow Antimicrobial Audit Tool (GAAT) Int J Antimicrob Agents 29 2007 693 699 (Pubitemid 46710368)
3. B.I. Eisenstein Treatment challenges in the management of complicated skin and soft-tissue infections Clin Microbiol Infect 14 Suppl. 2 2008 17 25
4. J. Segreti Review of question and answer session Int J Antimicrob Agents 34 Suppl. 1 2009 S36 S38
5. D.L. Stevens, A.L. Bisno, H.F. Chambers, E.D. Everett, P. Dellinger, and E.J. Goldstein Practice guidelines for the diagnosis and management of skin and soft-tissue infections Clin Infect Dis 41 2005 1373 1406 Erratum in: Clin Infect Dis 2005;41:1830; Clin Infect Dis 2006;42:1219 (Pubitemid 41581713)
6. B. Shrestha, B.M. Pokhrel, and T.M. Mohapatra Phenotypic characterization of nosocomial isolates of Staphylococcus aureus with reference to MRSA J Infect Dev Ctries 3 2009 554 560
7. M.R. Angel, V. Balaji, J.A.J. Prakash, K.N. Brahmadathan, and M.S. Mathews Prevalence of inducible clindamycin resistance in Gram positive organisms in a tertiary care centre Indian J Med Microbiol 26 2008 262 264
8. S. Mabe, and W.S. Champney A comparison of a new oral streptogramin XRP 2868 with quinupristin-dalfopristin against antibiotic-resistant strains of Haemophilus influenzae, Staphylococcus aureus, and Streptococcus pneumoniae Curr Microbiol 51 2005 363 366 (Pubitemid 41759131)
9. G.A. Pankuch, L.M. Kelly, G. Lin, A. Bryskier, C. Couturier, and M.R. Jacobs Activities of a new oral streptogramin XRP 2868, compared to those of other agents against Streptococcus pneumoniae and Haemophilus species Antimicrob Agents Chemother 47 2003 3270 3274 (Pubitemid 37229588)
10. E.J. Goldstein, D.M. Citron, C.V. Merriam, Y.A. Warren, K.L. Tyrrell, and H.T. Fernandez Comparative in vitro activities of XRP 2868, pristinamycin, quinupristin-dalfopristin, vancomycin, daptomycin, linezolid, clarithromycin, telithromycin, clindamycin, and ampicillin against anaerobic Gram-positive species, actinomycetes, and lactobacilli Antimicrob Agents Chemother 49 2005 408 413
11. M. Dupuis, and R. Leclercq Activity of a new oral streptogramin XRP2868, against Gram-positive cocci harboring various mechanisms of resistance to streptogramins Antimicrob Agents Chemother 50 2006 237 242 (Pubitemid 43042927)
12. D. Andes, and W.A. Craig Pharmacodynamics of a new streptogramin XRP 2868, in murine thigh and lung infection models Antimicrob Agents Chemother 50 2006 243 249 (Pubitemid 43042928)
13. V. Gualano, M. Felices, A. Tarral, C. Sable, and H. Merdjan Combined population (Pop) pharmacokinetic (PK) analysis of 6 phase I studies with NXL103 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 12-15 September 2009, San Francisco, CA 2009 ASM Press Washington, DC [Abstract A1-1945]
14. M. Rangaraju, A. Tarral, H. Merdjan, P. Levasseur, D. Chassard, and N. Audonnet Optimization of linopristin/flopristin dose ratio in NXL103 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 12-15 September 2009, San Francisco, CA 2009 ASM Press Washington, DC [Abstract A1-1943]
15. M. Wootton, R.A. Howe, R. Hillman, T.R. Walsh, P.M. Bennett, and A.P. MacGowan A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital J Antimicrob Chemother 47 2001 399 403 (Pubitemid 32303403)
16. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 8th ed. Document M07-A8. Wayne, PA: CLSI; 2008.
17. K.L. LaPlante, S.N. Leonard, D.R. Andes, W.A. Craig, and M.J. Rybak Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vitro pharmacodynamic models Antimicrob Agents Chemother 52 2008 2156 2162 (Pubitemid 351758553)
18. M. Rangaraju, J. Rey, and J. Hodgson NXL103 - oral streptogramin: a phase I, double-blind, single escalating oral dose study to evaluate safety, tolerability and pharmacokinetics in healthy adult male volunteers 16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 1-4 April 2006, Nice, France 2006 European Society of Clinical Microbiology and Infectious Diseases Basel, Switzerland [P-1512]
19. ®. Package insert. http://dailymed.nlm.nih.gov/ dailymed/archives/fdaDrugInfo.cfm?archiveid=843 [accessed 25 May 2011].
20. 14C]linezolid to healthy human subjects Drug Metab Dispos 29 2001 1136 1145 (Pubitemid 32660533)
21. J. Blaser In-vitro model for simultaneous simulations of the serum kinetics of two drugs with different half-lives J Antimicrob Chemother 15 Suppl. A 1985 125 130 (Pubitemid 15079556)
22. B. McGee, R. Dietze, D.J. Hadad, L.P. Molino, E.L. Maciel, and W.H. Boom Population pharmacokinetics of linezolid in adults with pulmonary tuberculosis Antimicrob Agents Chemother 53 2009 3981 3984
23. K.L. LaPlante, and L.A. Mermel In vitro activity of daptomycin and vancomycin lock solutions on staphylococcal biofilms in a central venous catheter model Nephrol Dial Transplant 22 2007 2239 2246 (Pubitemid 47248465)
24. F. Sevinc, J.M. Prins, R.P. Koopmans, P.N. Langendijk, P.M. Bossuyt, and J. Dankert Early switch from intravenous to oral antibiotics: guidelines and implementation in a large teaching hospital J Antimicrob Chemother 43 1999 601 606 (Pubitemid 29182316)
25. A.D. Politano, and R.G. Sawyer NXL-103, a combination of flopristin and linopristin, for the potential treatment of bacterial infections including community-acquired pneumonia and MRSA Curr Opin Investig Drugs 11 2010 225 236
26. A. Canu, and R. Leclercq Overcoming bacterial resistance by dual target inhibition: the case of streptogramins Curr Drug Targets Infect Disord 1 2001 215 225